Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

View ORCID ProfileRavindra Uppaluri, View ORCID ProfileKatie M. Campbell, Ann Marie Egloff, Paul Zolkind, View ORCID ProfileZachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, View ORCID ProfileRyan Jackson, Patrik Pipkorn, Loren P. Michel, View ORCID ProfileJessica Ley, Peter Oppelt, Gavin P. Dunn, View ORCID ProfileErica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, View ORCID ProfileDavid T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Jo, Matthew Stachler, View ORCID ProfileGlenn J. Hanna, View ORCID ProfileJason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, View ORCID ProfileWade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, View ORCID ProfileIan S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, View ORCID ProfileMalachi Griffith, View ORCID ProfileObi L. Griffith, Douglas R. Adkins
doi: https://doi.org/10.1101/2020.03.18.20037846
Ravindra Uppaluri
1Department of Surgery, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravindra Uppaluri
  • For correspondence: Ravindra_Uppaluri@DFCI.Harvard.edu
Katie M. Campbell
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katie M. Campbell
Ann Marie Egloff
1Department of Surgery, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Zolkind
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary L. Skidmore
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zachary L. Skidmore
Brian Nussenbaum
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randal C. Paniello
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason T. Rich
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan Jackson
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryan Jackson
Patrik Pipkorn
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren P. Michel
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Ley
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica Ley
Peter Oppelt
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavin P. Dunn
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
13Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica K. Barnell
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erica K. Barnell
Nicholas C. Spies
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianxiang Lin
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiantian Li
6Princess Margaret Cancer Center, University Health Network, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David T. Mulder
6Princess Margaret Cancer Center, University Health Network, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David T. Mulder
Youstina Hanna
6Princess Margaret Cancer Center, University Health Network, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iulia Cirlan
6Princess Margaret Cancer Center, University Health Network, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trevor J. Pugh
6Princess Margaret Cancer Center, University Health Network, Toronto, Canada
7Department of Medical Biophysics, Toronto, Canada
8Ontario Institute for Cancer Research, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tenny Mudianto
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Riley
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liye Zhou
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vickie Jo
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Stachler
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glenn J. Hanna
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Glenn J. Hanna
Jason Kass
1Department of Surgery, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason Kass
Robert Haddad
1Department of Surgery, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan D. Schoenfeld
3Radiation Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evisa Gjini
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Lako
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wade Thorstad
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
14Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wade Thorstad
Hiram A. Gay
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
14Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mackenzie Daly
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
14Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott J. Rodig
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
5Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian S. Hagemann
15Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ian S. Hagemann
Dorina Kallogjeri
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay F. Piccirillo
10Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca D. Chernock
15Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malachi Griffith
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Malachi Griffith
Obi L. Griffith
9McDonnell Genome Institute and Department of Genetics, Washington University School of Medicine, St. Louis, MO
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Obi L. Griffith
Douglas R. Adkins
11Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
12Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

SUMMARY

Background Pembrolizumab improved survival of patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this phase 2 trial were to determine if pembrolizumab administered to patients with resectable locally advanced, human papillomavirus (HPV)-unrelated HNSCC would be safe, result in pathologic tumor response (pTR), and lower the relapse rate.

Methods Neoadjuvant pembrolizumab (200 mg) was administered 2-3 weeks before surgery. Resection of the primary tumor and involved/at-risk nodes was performed. Post-operative (chemo) radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) were to receive adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10-49%), and pTR-2 (≥50%). Co-primary endpoints were pTR-2 among all patients, and one-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 expression and T-cell infiltration with pTR were assessed, and tumor clonal dynamics were evaluated. Analyses were done per protocol. This trial is registered with ClinicalTrials.gov(NCT02296684), and is ongoing but closed to accrual.

Findings Between June 30, 2015, and March 30, 2018, 36 patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3-4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). pTR ≥10% correlated with baseline tumor PD-L1 expression, immune infiltrate, and IFN-γ pathway activity. Matched sample analysis showed compensatory upregulation of multiple immune inhibitory checkpoints in patients with pTR-0, and confirmed that clonal loss occurred in some patients. The one-year relapse rate among the eighteen patients with high-risk pathology was 16.7% (95%CI: 3.6-41.4%).

Conclusions Among patients with locally advanced, HPV-unrelated HNSCC, neoadjuvant pembrolizumab was safe, and resulted in pTR-1 or pTR-2 in 44% of patients. The one-year relapse rate in patients with high-risk-pathology was lower than historical.

Funding Merck, NCI, NIDCR, NHGRI and The V Foundation.

  • pembrolizumab
  • head and neck squamous-cell carcinoma
  • neoadjuvant therapy

Competing Interest Statement

RU is on the scientific advisory board at Merck. RIH receives research support and does consulting for BMS, Merck, Astra Zeneca, Pfizer, and Celgene. GJH receives research support and does consulting for BMS, Merck, Astra Zeneca, Pfizer, and Celgene. JS consulted and/ or received grants from Bristol-Myers Squibb, Merck, AstraZeneca, Debiopharm, Nanobiotix, Regeneron and Tilos Therapeutics. RU and DA report research funding from Merck as part of the work under consideration for publication. DA reports personal fees for advisory role/consulting from Pfizer, Eli Lilly, Merck, Celgene, Cue Biopharma, and Loxo Oncology, and research funding from Pfizer, Eli Lilly, Merck, Celgene, Novartis, AstraZeneca, Atara, Blueprint Medicine, CellCeutix, Celldex, Enzychem, Gliknik, BMS, Kura, Medimmune, Exelixis, Innate, Matrix Biomed, and Polaris, outside the submitted work. EKB is a shareholder, executive, and a board member at Geneoscopy LLC. KMC is a shareholder in Geneoscopy LLC.

Clinical Trial

NCT02296684

Funding Statement

We recognize the support of the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Missouri, the Clinical Trials Core, the Biostatistics Shared Resource, and the Center for Biomedical Informatics. The Siteman Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842. MG is funded by the National Human Genome Research Institute (NIH NHGRI R00HG007940), OLG by the National Cancer Institute (NIH/NCI K22CA188163, NIH/NCI U01CA209936 and NIH/NCI U24CA237719) and a Cancer Research Foundation Young Investigator Award. RU is funded by the National Institute for Dental and Craniofacial Research (NIH/NIDCR R01DE024403, R01DE027736) and a V Foundation Translational Research Award. Clinical trial support was through a Merck Investigator Studies Program award to RU/DRA.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# Co-senior authors

Data Availability

Sequencing data have been deposited in dbGaP (phs001623).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 20, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren P. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Jo, Matthew Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
medRxiv 2020.03.18.20037846; doi: https://doi.org/10.1101/2020.03.18.20037846
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff, Paul Zolkind, Zachary L. Skidmore, Brian Nussenbaum, Randal C. Paniello, Jason T. Rich, Ryan Jackson, Patrik Pipkorn, Loren P. Michel, Jessica Ley, Peter Oppelt, Gavin P. Dunn, Erica K. Barnell, Nicholas C. Spies, Tianxiang Lin, Tiantian Li, David T. Mulder, Youstina Hanna, Iulia Cirlan, Trevor J. Pugh, Tenny Mudianto, Rachel Riley, Liye Zhou, Vickie Jo, Matthew Stachler, Glenn J. Hanna, Jason Kass, Robert Haddad, Jonathan D. Schoenfeld, Evisa Gjini, Ana Lako, Wade Thorstad, Hiram A. Gay, Mackenzie Daly, Scott J. Rodig, Ian S. Hagemann, Dorina Kallogjeri, Jay F. Piccirillo, Rebecca D. Chernock, Malachi Griffith, Obi L. Griffith, Douglas R. Adkins
medRxiv 2020.03.18.20037846; doi: https://doi.org/10.1101/2020.03.18.20037846

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (163)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (865)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8585)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1765)
  • Geriatric Medicine (168)
  • Health Economics (373)
  • Health Informatics (1250)
  • Health Policy (624)
  • Health Systems and Quality Improvement (470)
  • Hematology (197)
  • HIV/AIDS (379)
  • Infectious Diseases (except HIV/AIDS) (10333)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1691)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (264)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (254)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (255)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1782)
  • Public and Global Health (3862)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (522)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)